PCI Pharma Services Acquires Bellwyck Pharma Services
February 11, 2020
PCI Pharma Services announced the acquisition of Bellwyck Pharma Services, a Toronto-headquartered clinical and commercial packaging, labeling and clinical trial services provider. The deal adds four GMP-compliant facilities in the U.S., Germany and Canada to PCI's global network and expands PCI's clinical trial service footprint into Canada and continental Europe.
- Buyers
- PCI Pharma Services
- Targets
- Bellwyck Pharma Services
- Industry
- Healthcare Services
- Location
- Ontario, Canada
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
MAX Solutions Acquires Bellwyck Packaging Inc.
January 8, 2024
Manufacturing
MAX Solutions Inc. has acquired Bellwyck Packaging, a Canadian manufacturer of folding cartons, labels and rigid packaging with manufacturing sites in Ontario and British Columbia. The acquisition expands MAX Solutions' manufacturing capabilities and footprint in key end markets including pharma, health & beauty and horticulture; Bellwyck's owners will remain investors and advisors to the combined business.
-
Kohlberg & Mubadala Acquire Majority Stake in PCI Pharma Services
December 1, 2020
Healthcare Services
Private equity firm Kohlberg & Company acquired a majority stake in PCI Pharma Services, with Mubadala Investment Company joining as a significant investor and Partners Group retaining a minority stake. The deal (signed August 24, 2020 and closed December 1, 2020) positions PCI to expand capabilities—such as sterile fill/finish and high-potency manufacturing—and further geographic reach while continuing to serve pharmaceutical and biopharmaceutical customers from its Philadelphia headquarters.
-
Bain Capital and Kohlberg Lead Strategic Investment in PCI Pharma Services
July 14, 2025
Healthcare Services
PCI Pharma Services, a Philadelphia-based contract development and manufacturing organization (CDMO), received a strategic growth investment co-led by Bain Capital and existing lead investor Kohlberg, with significant reinvestment from Mubadala and a continuing minority stake from Partners Group. The capital will be used to accelerate PCI's organic and inorganic growth, expand sterile fill-finish and specialized manufacturing capacity, and broaden its geographic footprint to support biopharma customers and U.S. pharmaceutical supply-chain resilience.
-
ProAmpac Acquires Belle-Pak Packaging
February 22, 2022
Packaging
ProAmpac, a Cincinnati-based flexible packaging company owned by Pritzker Private Capital, acquired Belle-Pak Packaging, a Markham, Ontario manufacturer of flexible packaging products. The add-on strengthens ProAmpac's presence in Canada and expands its capabilities and customer reach in e-commerce, healthcare and logistics end markets.
-
PCI Pharma Services Acquires Lyophilization Services of New England (LSNE)
October 12, 2021
Pharmaceuticals
PCI Pharma Services (PCI) has acquired Lyophilization Services of New England, Inc. (LSNE), a Bedford, New Hampshire–based CDMO, from private equity firm Permira. The deal expands PCI’s global sterile fill-finish and lyophilization capabilities, adding five FDA-approved facilities (U.S. and Spain) and strengthening its end-to-end manufacturing offering for biologics and injectables.
-
GSK Acquires BELLUS Health
April 18, 2023
Biotechnology
GSK plc agreed to acquire Canada-based late-stage biopharmaceutical company BELLUS Health for US$14.75 per share, representing an approximate total equity value of US$2.0 billion. The acquisition gives GSK access to camlipixant, a Phase III P2X3 antagonist for refractory chronic cough, and is expected to close in Q3 2023 subject to approvals.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.